Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
English Version English Version
  MedUni Wien  trenner  Intranet  trenner  MedUni Wien - Shop  trenner  Universitätsbibliothek  trenner  Universitätsklinikum AKH Wien  trenner
 
Krebsforschung.png
 
 
 
Hauptnavigation
  • Home
  • Mission Statement
    • Chronik
    • 50 Jahre Institut für Krebsforschung
    • Imagevideo: Institut für Krebsforschung
  • Forschung
    • Forschungsschwerpunkte
    • Forschungsgruppen
    • Wissenschaftliche Services - Core Facilities
  • Lehre
    • Vorlesungen und Seminare des Institutes
    • Universitätslehrgang Toxikologie für Postgraduierte
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Programm Malignant Diseases
    • PhD Programm Clinical and Experimental Oncology
  • Kontakt
    • Kontakt
    • Lageplan
 
Forschung / Forschungsschwerpunkte / Angewandte und experimentelle Onkologie / Klaus Holzmann / Research Projects
 
Subnavigation
  • Forschungsschwerpunkte
    • Zelluläre und molekulare Tumorbiologie
    • Angewandte und experimentelle Onkologie
      • Walter Berger
      • Martin Filipits
      • Petra Heffeter
      • Michael Grusch
      • Klaus Holzmann
        • Research Projects
        • Group Members
        • Former Group Members
        • Teaching
        • Short CV
      • Hedwig Sutterlüty
    • Sicherheit chemischer Substanzen und Krebsprävention
    • Progression und Metastasierung von Tumoren
  • Forschungsgruppen
  • Wissenschaftliche Services - Core Facilities


Inhaltsbereich

Immortality and growth factor signaling

Reactivation and expression of telomerase is an important hallmark for around 85% of all tumors to maintain telomeres and gain immortality by overcoming molecular senescence. ALT is less commonly used, but show high prevalence in sarcoma and astrocytoma. In cooperation with clinical partners we focused on the role of TMMs in human glioblastoma multiform (GBM), an aggressive form of astrocytoma brain tumors (Sampl et al, 2012). Our data support the known high prevalence of ALT in low-grade astrocytoma and better clinical outcome in GBM with ALT. TMM was evaluated by measuring TA and by detection of long telomeres typically seen with ALT. TA positive cells show mean of 5-10 kbp, whereas in ALT cells up to 20 kbp telomere length (TL). Long non–coding telomeric repeat–containing RNA transcripts (TERRA or TelRNA) have been reported as key component of telomeres with inhibitory function on telomerase. We demonstrated by qPCR that TERRA expression clearly correlates with tumor grade and TMM (Figure 1). TERRA expression correlated to outcome of this patient series indicating that TERRA may be prognostic in astrocytoma. Next, we set up a recombinant TERRA expression system (Kreilmeier et al, 2016a) to evaluate TERRA effects in vitro (Figure 2). With a commercial partner we used this system to study combinatorial effects in tumor cells. Furthermore, we were able to identify recently the ALT mechanisms in canine tumors, important for comparative research (Kreilmeier et al, 2016b).

Figure 1: TERRA relative quantity (RQ) expression levels compared with non-tumor (NT) and tumor grade II, III and IV (=GBM), and with TMM in astrocytoma patient tissue.
Figure 2: Recombinant TERRA adeno- and lentivirus (AV and LV) expression constructs. TERRA expression constructs contain telomeric hexanucleotide repeat variant sequences under control of hH1 or CMV promoter for TERRA without or with polyadenylation. TERRA detected by FISH localized in interphase nuclei of LV clones from SW480 cells. Telomerase activity (TA) measured by telomeric repeat amplification protocol (TRAP) assay in tumor cell lines with LV and AV constructs. TERRA inhibits TA as compared to control (eGFP).

In cooperation with partners from Veterinary Universities we performed FGF receptor (FGFR) expression studies on soft tissue sarcoma (STS) in a comparative setting on human and canine species (Schweiger et al, 2015). We identified FGFR1 as most abundant expressed member of the FGFR family in STS. Alternative splicing of the IgIII loop of FGFRs 1-3 leads to b- and c-variants, involved in epithelial mesenchymal transition important for metastatic features during tumor progression. We developed STS and colorectal cancer (CRC) tumor cell models with splice reporter systems using fluorescent proteins (Holzmann et al, 2012). Such systems allow in vivo and in vitro real-time observation of splice choices in single cells (Figure 3). Together with clinical partners, we identified ESRP1 and ESRP2 splicing regulatory proteins as essential for FGFR variant splicing in CRC progression and as potential independent prognostic markers for patient survival (Deloria et al, 2016).

Figure 3: Development of FGFR 1-3 IIIb/IIIc splice reporter systems. Schematic of bichromatic (green, red) fluorescence reporter constructs for detection of alternative splicing of FGFR2 IIIc exons results transcripts with different reading frames for green or red chimeric fluorescence proteins. FGFR2 IIIc reporter applied by adenoviral (AV) construct to study splicing in individual single CRC cells depending on a stimulus.
 
Drucken
 
 
© MedUni Wien | Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt